Kenneth S Thomson1, Ellen Smith Moland. 1. Center for Research in Anti-Infectives and Biotechnology, Department of Medical Microbiology and Immunology, Creighton University School of Medicine, Omaha, NE 68178, USA. kstaac@creighton.edu
Abstract
OBJECTIVE: To compare the in vitro activities of the carbapenem, CS-023, four representative beta-lactam antibiotics and levofloxacin, against 970 Gram-positive or Gram-negative US clinical isolates. METHODS: Susceptibilities of bacteria chosen for their varying levels of resistance to the comparator agents were determined by NCCLS microdilution methodology. RESULTS: CS-023 exhibited activity comparable to that of imipenem against most Gram-positive isolates, but was approximately 8-fold more potent against oxacillin-resistant staphylococci. It was comparable to meropenem against most Gram-negative isolates, but was 4- to 8-fold more potent against five isolates of meropenem-resistant Pseudomonas aeruginosa. CONCLUSIONS: If tissue and body fluid concentrations >8 mg/L can safely be achieved, further studies of CS-023 are warranted to determine its clinical efficacy.
OBJECTIVE: To compare the in vitro activities of the carbapenem, CS-023, four representative beta-lactam antibiotics and levofloxacin, against 970 Gram-positive or Gram-negative US clinical isolates. METHODS: Susceptibilities of bacteria chosen for their varying levels of resistance to the comparator agents were determined by NCCLS microdilution methodology. RESULTS:CS-023 exhibited activity comparable to that of imipenem against most Gram-positive isolates, but was approximately 8-fold more potent against oxacillin-resistant staphylococci. It was comparable to meropenem against most Gram-negative isolates, but was 4- to 8-fold more potent against five isolates of meropenem-resistant Pseudomonas aeruginosa. CONCLUSIONS: If tissue and body fluid concentrations >8 mg/L can safely be achieved, further studies of CS-023 are warranted to determine its clinical efficacy.
Authors: Navita L Mallalieu; Siân Lennon; Mei Liu; Christopher Kirkpatrick; Richard Robson; Eric Luedin; Brian E Davies Journal: Antimicrob Agents Chemother Date: 2008-04-28 Impact factor: 5.191
Authors: Navita L Mallalieu; Siân Lennon; Thorold Guy; Mei Liu; Eric Luedin; Brian E Davies Journal: Br J Clin Pharmacol Date: 2009-04 Impact factor: 4.335